Obesity Clinical Trials in Rochester, New York

9 studies are recruiting for obesity in Rochester, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

   The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newl…

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Rochester Clinical Research, LLC, Rochester, New York

   Locations

   56 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06143956 on ClinicalTrials.gov

2. A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

   The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes. About 950 adults will be in this study. Berobenatide will be compared to a plac…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Rochester Clinical Research, LLC, Rochester, New York

   Locations

   50 in total

   Run by

   Pfizer

   See if you can join NCT07595549 on ClinicalTrials.gov

3. Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

   The primary objective of this trial is to demonstrate that maridebart cafraglutide is superior to placebo when given as an adjunct to standard of care with respect to reducing cardiovascular (CV) morbidity and mortality.

   Stage

   Phase 3

   Ages

   45 to 99

   Site

   Rochester Clinical Research, Rochester, New York

   Locations

   783 in total

   Run by

   Amgen

   See if you can join NCT07037433 on ClinicalTrials.gov

4. Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

   The primary objective of the study is to determine the effects of ribupatide (KAI-9531) subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Kailera Clinical Site, Rochester, New York

   Locations

   104 in total

   Run by

   Kailera

   See if you can join NCT07284875 on ClinicalTrials.gov

5. Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

   The primary objective of this trial is to evaluate the long-term efficacy, safety, and tolerability of maridebart cafraglutide in participants with obesity or overweight. Trial 20250197 is an extension of trial 20210181 (NCT06858839).

   Stage

   Phase 3

   Ages

   18 to 99

   Site

   Rochester Clinical Research, Rochester, New York

   Locations

   87 in total

   Run by

   Amgen

   See if you can join NCT07684235 on ClinicalTrials.gov

6. A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

   The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants w…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Rochester Clinical Research, LLC, Rochester, New York

   Locations

   162 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07321886 on ClinicalTrials.gov

7. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

   This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Rochester, Rochester, New York

   Locations

   838 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07567001 on ClinicalTrials.gov

8. A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

   The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to examine the body weight-lowering efficacy and safety of macupatide plus eloralintide compared with placebo in participants with obesity or overweight and without type 2 diabetes. Participation will …

   Stage

   Phase 2

   Ages

   18 to 75

   Site

   Rochester Clinical Research, LLC, Rochester, New York

   Locations

   40 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07589608 on ClinicalTrials.gov

9. Body Composition Related Evaluation of Airway Tone and Hyper-rEactivity Using Oscillometry

   This study will determine if airway resistance to airflow and pressure, measured by Oscillometry, is associated with abnormal findings on methacholine challenge testing and whether these findings are associated with body habitus,

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Rochester Medical Center, Rochester, New York

   Run by

   University of Rochester

   See if you can join NCT07356310 on ClinicalTrials.gov